Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Status:
Terminated
Trial end date:
2019-07-23
Target enrollment:
Participant gender:
Summary
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells)
to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared
to post-transplant cyclophosphamide.